Follow
Rocco Piazza
Title
Cited by
Cited by
Year
Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib
C Gambacorti-Passerini, L Antolini, FX Mahon, F Guilhot, M Deininger, ...
Journal of the National Cancer Institute 103 (7), 553-561, 2011
5142011
Activity of bosutinib, dasatinib, and nilotinib against 18 imatinib-resistant BCR/ABL mutants.
S Redaelli, R Piazza, R Rostagno, V Magistroni, P Perini, M Marega, ...
Journal of clinical oncology: official journal of the American Society of …, 2008
5142008
Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias
CB Gambacorti-Passerini, RH Gunby, R Piazza, A Galietta, R Rostagno, ...
The lancet oncology 4 (2), 75-85, 2003
5072003
In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells
M Puttini, AML Coluccia, F Boschelli, L Cleris, E Marchesi, ...
Cancer research 66 (23), 11314-11322, 2006
4662006
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia
R Piazza, S Valletta, N Winkelmann, S Redaelli, R Spinelli, A Pirola, ...
Nature genetics 45 (1), 18-24, 2013
4132013
Crizotinib in advanced, chemoresistant anaplastic lymphoma kinase–positive lymphoma patients
C Gambacorti Passerini, F Farina, A Stasia, S Redaelli, M Ceccon, ...
Journal of the National Cancer Institute 106 (2), djt378, 2014
3022014
Age and d PCR can predict relapse in CML patients who discontinued imatinib: The ISAV study
S Mori, E Vagge, P Le Coutre, E Abruzzese, B Martino, E Pungolino, ...
American journal of hematology 90 (10), 910-914, 2015
2282015
In reply to'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'
C Gambacorti, L Tornaghi, A Franceschino, R Piazza, G Corneo, ...
Nature medicine 13 (1), 13-14, 2007
1602007
A diastrophic dysplasia sulfate transporter (SLC26A2) mutant mouse: morphological and biochemical characterization of the resulting chondrodysplasia phenotype
A Forlino, R Piazza, C Tiveron, SD Torre, L Tatangelo, L Bonafe, ...
Human molecular genetics 14 (6), 859-871, 2005
1482005
Epigenetic silencing of BIM in glucocorticoid poor-responsive pediatric acute lymphoblastic leukemia, and its reversal by histone deacetylase inhibition
PS Bachmann, RG Piazza, ME Janes, NC Wong, C Davies, A Mogavero, ...
Blood, The Journal of the American Society of Hematology 116 (16), 3013-3022, 2010
1402010
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia
CB Gambacorti-Passerini, C Donadoni, A Parmiani, A Pirola, S Redaelli, ...
Blood, The Journal of the American Society of Hematology 125 (3), 499-503, 2015
1252015
Three novel patient‐derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors
S Redaelli, L Mologni, R Rostagno, R Piazza, V Magistroni, M Ceccon, ...
American journal of hematology 87 (11), E125, 2012
1232012
Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: A systematic review and a meta-analysis
L Campiotti, MB Suter, L Guasti, R Piazza, C Gambacorti-Passerini, ...
European Journal of Cancer 77, 48-56, 2017
1042017
Lorlatinib treatment elicits multiple on-and off-target mechanisms of resistance in ALK-driven cancer
S Redaelli, M Ceccon, M Zappa, GG Sharma, C Mastini, M Mauri, ...
Cancer research 78 (24), 6866-6880, 2018
892018
SETBP1 induces transcription of a network of development genes by acting as an epigenetic hub
R Piazza, V Magistroni, S Redaelli, M Mauri, L Massimino, A Sessa, ...
Nature communications 9 (1), 2192, 2018
712018
Mutational signatures and heterogeneous host response revealed via large-scale characterization of SARS-CoV-2 genomic diversity
A Graudenzi, D Maspero, F Angaroni, R Piazza, D Ramazzotti
Iscience 24 (2), 2021
652021
Treatment efficacy and resistance mechanisms using the second-generation ALK inhibitor AP26113 in human NPM-ALK–positive anaplastic large cell lymphoma
M Ceccon, L Mologni, G Giudici, R Piazza, A Pirola, D Fontana, ...
Molecular Cancer Research 13 (4), 775-783, 2015
642015
Epigenetic silencing of the proapoptotic gene BIM in anaplastic large cell lymphoma through an MeCP2/SIN3a deacetylating complex
R Piazza, V Magistroni, A Mogavero, F Andreoni, C Ambrogio, R Chiarle, ...
Neoplasia 15 (5), 511-IN17, 2013
562013
EXT 1 Gene Mutation Induces Chondrocyte Cytoskeletal Abnormalities and Defective Collagen Expression in the Exostoses
L Legeai‐Mallet, A Rossi, C Benoist‐Lasselin, R Piazza, JF Mallet, ...
Journal of bone and mineral research 15 (8), 1489-1500, 2000
532000
The co-evolution of the genome and epigenome in colorectal cancer
T Heide, J Househam, GD Cresswell, I Spiteri, C Lynn, M Mossner, ...
Nature 611 (7937), 733-743, 2022
522022
The system can't perform the operation now. Try again later.
Articles 1–20